Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in disease recurrence or death risk as adjuvant therapy in the Phase 3 LIBRETTO-432 trial. The study enrolled patients with early-stage RET fusion-positive non-small cell lung cancer following definitive surgery. The primary endpoint was disease-free survival, which the drug met with high statistical significance. The hazard ratio supported the magnitude of benefit observed across prespecified subgroups.
Retevmo holds accelerated FDA approval and EMA conditional marketing authorization for RET-altered NSCLC. Lilly must submit LIBRETTO-432 data as a supplemental NDA under 21 CFR 314.70 to convert the indication. The EMA's PRIME-designated selpercatinib will require a Type II variation under EU regulation 1234/2008. Both agencies typically review adjuvant oncology data within six months of submission. Approval would expand the adjuvant label into early-stage disease, establishing a new standard of care for biomarker-selected patients.
Roche's Alecensa and Pfizer's lorlatinib compete in the ALK-positive NSCLC adjuvant space but lack RET activity. Retevmo's efficacy positions it as the only targeted adjuvant option for RET fusion-positive patients following curative-intent surgery. Lilly expects to file the supplemental NDA by Q4 2026. The data strengthens Lilly's oncology franchise against AstraZeneca's Tagrisso in the broader adjuvant NSCLC market, where biomarker-driven segmentation accelerates commercial value.